Hookipa Pharma (HOOK) to Release Quarterly Earnings on Thursday

Hookipa Pharma (NASDAQ:HOOK) is set to post its quarterly earnings results before the market opens on Thursday, May 9th. Analysts expect Hookipa Pharma to post earnings of ($0.12) per share for the quarter.

Hookipa Pharma (NASDAQ:HOOK) last released its quarterly earnings results on Friday, March 22nd. The company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.20) by $0.09. The company had revenue of $7.41 million for the quarter, compared to analyst estimates of $3.60 million. Hookipa Pharma had a negative return on equity of 72.30% and a negative net margin of 405.28%. On average, analysts expect Hookipa Pharma to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Hookipa Pharma Stock Performance

NASDAQ HOOK traded down $0.01 on Wednesday, hitting $0.82. 58,672 shares of the stock were exchanged, compared to its average volume of 735,151. Hookipa Pharma has a 52-week low of $0.41 and a 52-week high of $2.05. The firm has a market capitalization of $80.64 million, a P/E ratio of -0.97 and a beta of 0.92. The stock has a fifty day moving average price of $0.78 and a two-hundred day moving average price of $0.68.

Wall Street Analyst Weigh In

Several equities analysts recently commented on HOOK shares. Royal Bank of Canada reiterated an “outperform” rating and set a $5.00 price target on shares of Hookipa Pharma in a report on Monday, March 25th. HC Wainwright cut their target price on Hookipa Pharma from $6.50 to $5.00 and set a “buy” rating on the stock in a research note on Friday, April 26th.

Hookipa Pharma Company Profile

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.